| abstract |
The present application relates to novel combinations of at least two components (component a and component B) for the treatment and/or prevention of diseases: component a is an IRAK4 inhibitory compound of formula (I) as defined herein, or a diastereomer, enantiomer, metabolite, salt, solvate or solvate of a salt thereof; component B is a BTK inhibitory compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C, which is a pharmaceutical product; wherein one or both of compounds a and B as defined above are optionally present in a pharmaceutical preparation prepared for simultaneous, separate or sequential administration, and to the use thereof for the manufacture of a medicament for the treatment and/or prevention of a disease, in particular for the treatment and/or prevention of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis. |